Literature DB >> 6753894

Long-term experience of captopril in the treatment of primary (essential) hypertension.

B E Karlberg, J Asplund, S Wettre, K P Ohman, O R Nilsson.   

Abstract

1 Forty-one patients with primary (essential) hypertension were treated with captopril alone or in combination with hydrochlorothiazide for 12-36 months. 2 During an initial dose-titration period mean blood pressure fell from 174/111 mm Hg to 134/88 mm Hg supine and from 170/116 mm Hg to 126/93 mm Hg standing after 3 months' treatment. 3 During long-term treatment with unchanged or reduced doses of captopril or hydrochlorothiazide, or both, blood pressure remained substantially reduced. Mean supine blood pressure at 24 months was 136/90 mm Hg and at 36 months 138/90 mm Hg. 4 In 12 patients with clearly defined low renin (essential) hypertension initial blood pressure reduction was less than in patients with normal renin hypertension after 1 month's treatment (162/102 mm Hg v 143/92 mm Hg). After 24 months of treatment, however, the treatment results were similar in the two groups. 5 Except for one case of reversible proteinuria no serious side effects were seen during treatment periods of up to three years. 6 Captopril alone or in combination with hydrochlorothiazide seems to be an effective and safe drug in the long-term treatment of primary hypertension.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6753894      PMCID: PMC1427527          DOI: 10.1111/j.1365-2125.1982.tb02070.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients.

Authors:  H R Brunner; H Gavras; B Waeber; G R Kershaw; G A Turini; R A Vukovich; D N McKinstry; I Gavras
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

2.  Acute and chronic effects of the angiotensin-converting enzyme inhibitor captopril in severe hypertension.

Authors:  J Havelka; H Vetter; A Studer; P Greminger; T Lüscher; S Wollnik; W Siegenthaler; W Vetter
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

3.  Captopril in the treatment of moderate to severe hypertension. A long-term study.

Authors:  B Carlier; J F De Plaen; C Van Ypersele de Strihou
Journal:  Acta Clin Belg       Date:  1981       Impact factor: 1.264

4.  Plasma and urinary aldosterone and their interrelations with blood pressure, plasma renin activity and urinary electrolytes in normotensive subjects.

Authors:  K Tolagen; B E Karlberg
Journal:  Scand J Clin Lab Invest       Date:  1978-05       Impact factor: 1.713

5.  Relationships between blood pressure, age, plasma renin activity and electrolyte excretion in normotensive subjects.

Authors:  B E Karlberg; K Tolagen
Journal:  Scand J Clin Lab Invest       Date:  1977-10       Impact factor: 1.713

6.  Captopril, an orally active converting enzyme inhibitor, in the treatment of primary hypertension. A controlled long-term study with reference to initial plasma renin activity.

Authors:  B E Karlberg; J Asplund; O R Nilsson; S Wettre; K P Ohman
Journal:  Acta Med Scand       Date:  1981

7.  Long-term efficacy of captopril in renovascular and essential hypertension.

Authors:  D B Case; S A Atlas; R M Marion; J H Laragh
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

  7 in total
  5 in total

Review 1.  Control of energy balance by the brain renin-angiotensin system.

Authors:  Kristin E Claflin; Justin L Grobe
Journal:  Curr Hypertens Rep       Date:  2015-05       Impact factor: 5.369

Review 2.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

3.  The calcium antagonists PY 108-068 and verapamil diminish the effects of angiotensin II: sites of interaction in the peripheral circulation of anaesthetized cats.

Authors:  R P Hof
Journal:  Br J Pharmacol       Date:  1984-05       Impact factor: 8.739

4.  [Results of a 5-year study with captopril in patients with severe therapy-resistant hypertension].

Authors:  J Schrader; G Schoel; F Scheler
Journal:  Klin Wochenschr       Date:  1986-08-01

5.  Captopril for refractory hypertension in patients with impaired renal function.

Authors:  M S Laher; P O'Regan; J F O'Donohoe; T B Counihan
Journal:  J R Soc Med       Date:  1985-05       Impact factor: 5.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.